Every 10-Q that QUANTUM GENESIS AI CORP (QGAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QGAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QGAI filings page.
Quantum Genesis AI Corp. reported no revenue for the quarter and nine months ended April 30, 2026 and remains a pre-revenue company. For the nine-month period, it posted a net loss of $4,404,437, driven largely by a $4,325,872 loss on settlement of debt, compared with a net loss of $161,092 a year earlier. Cash was only $59 at April 30, 2026 against current liabilities of $443,313, resulting in a working capital deficit of $443,254 and total stockholders’ deficit of $443,254. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern and notes reliance on future financing without firm agreements. During the period, the company issued 2,010,000 common shares valued at $4,401,900 to settle $76,028 of notes and interest, creating significant non-cash loss and dilution. Operating expenses declined year over year due to lower professional fees, but the business continues to fund itself mainly through promissory notes. The company also formalized assignment of key enzyme-design intellectual property and discloses that its disclosure controls and internal control over financial reporting are not effective, with material weaknesses tied to limited staffing and lack of an audit committee.
Quantum Genesis AI Corp. filed an amended quarterly report to expand its discussion of intellectual property and update management’s analysis. The company reported no revenue for the three and six months ended January 31, 2026, but recorded a large net loss driven by a debt settlement.
For the six-month period, net loss was $4,379,525, contributing to an accumulated deficit of $10,016,092 and a working capital deficit of $418,342. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern without new financing. The amendment also formalizes assignment of enzyme design–related intellectual property, including rights tied to a U.S. patent application, from the CEO to the company under a prior asset purchase agreement.
Quantumzyme Corp. filed an Amendment No. 1 to its quarterly report for the three months ended October 31, 2025, mainly to expand management’s discussion, especially around intellectual property acquired under a February 21, 2023 Asset Purchase Agreement.
The company generated no revenue in the quarter, recorded operating expenses of $39,196 and a net loss of $49,868, narrower than the prior-year loss of $65,523. Other expenses increased to $10,672, driven by higher interest on additional debt.
As of October 31, 2025, Quantumzyme reported current assets of $184, current liabilities of $490,769, and a working capital deficit of $490,585, alongside an accumulated deficit of $5,686,435, leading to a stated substantial doubt about its ability to continue as a going concern.
The amendment also clarifies that proprietary enzyme design technologies and related know-how, including a U.S. patent application on modified polypeptides for ibuprofen synthesis filed November 2, 2023 in the CEO’s name, have been formally assigned to the company via an Assignment Agreement effective as of that filing date.
Quantum Genesis AI Corp. reported no revenue and a sharply higher net loss as it restructures its balance sheet. For the quarter ended January 31, 2026, the company recorded a net loss of $4,329,657, driven mainly by a non‑cash $4,325,872 loss on conversion of debt.
For the six months, the net loss was $4,379,525 and the accumulated deficit reached $10,016,092. Cash was only $59 with a working capital deficit of $418,342 and notes payable of $232,066, underscoring severe liquidity pressure.
The company issued 2,010,000 common shares valued at $4,401,900 to settle $76,028 of debt and interest, creating the large non‑cash loss and diluting shareholders. Management states there is substantial doubt about its ability to continue as a going concern and acknowledges material weaknesses in internal controls over financial reporting.